Amyris (NASDAQ:AMRS) was downgraded by ValuEngine from a "buy" rating to a "hold" rating in a research report issued on Tuesday, ValuEngine reports.
A number of other brokerages also recently weighed in on AMRS. Zacks Investment Research downgraded shares of Amyris from a "hold" rating to a "sell" rating in a research note on Friday, June 12th. Oppenheimer assumed coverage on shares of Amyris in a research report on Friday, June 5th. They issued a "buy" rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. The stock currently has a consensus rating of "Hold" and a consensus price target of $7.83.
NASDAQ AMRS traded down $0.22 during trading hours on Tuesday, reaching $4.21. 1,619,700 shares of the company's stock were exchanged, compared to its average volume of 2,444,091. The firm has a fifty day moving average of $4.24 and a 200-day moving average of $3.22. Amyris has a one year low of $1.40 and a one year high of $6.07. The stock has a market cap of $722.33 million, a PE ratio of -1.66 and a beta of 0.50.
Amyris (NASDAQ:AMRS) last announced its earnings results on Friday, May 8th. The biotechnology company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.37). The firm had revenue of $29.13 million during the quarter, compared to the consensus estimate of $34.51 million. On average, equities analysts forecast that Amyris will post -0.75 earnings per share for the current fiscal year.
In other Amyris news, Director Frank Kung bought 3,689,225 shares of the business's stock in a transaction on Friday, June 5th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $11,067,675.00. Following the transaction, the director now owns 2,932 shares in the company, valued at approximately $8,796. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 39.70% of the company's stock.
Several institutional investors have recently modified their holdings of the business. Citigroup Inc. lifted its stake in shares of Amyris by 15.0% in the 1st quarter. Citigroup Inc. now owns 26,532 shares of the biotechnology company's stock valued at $68,000 after purchasing an additional 3,456 shares during the period. Wells Fargo & Company MN boosted its holdings in Amyris by 16.6% during the first quarter. Wells Fargo & Company MN now owns 43,416 shares of the biotechnology company's stock worth $111,000 after buying an additional 6,174 shares during the last quarter. TrinityPoint Wealth LLC grew its position in shares of Amyris by 39.3% during the 1st quarter. TrinityPoint Wealth LLC now owns 25,511 shares of the biotechnology company's stock worth $65,000 after buying an additional 7,200 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Amyris by 4.2% in the 4th quarter. Nuveen Asset Management LLC now owns 190,559 shares of the biotechnology company's stock valued at $589,000 after acquiring an additional 7,611 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Amyris by 48.7% in the 1st quarter. SG Americas Securities LLC now owns 24,501 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 8,026 shares during the period. Institutional investors own 29.13% of the company's stock.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Read More: How is net asset value different from market price?
To view ValuEngine's full report, visit ValuEngine's official website.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]